S&P 500   4,387.25 (-0.52%)
DOW   34,410.84 (+0.13%)
QQQ   347.16 (-1.74%)
AAPL   160.17 (-0.90%)
MSFT   291.99 (-1.48%)
FB   303.68 (-1.63%)
GOOGL   2,568.25 (-1.83%)
AMZN   2,812.47 (-2.71%)
TSLA   924.20 (-0.62%)
NVDA   225.15 (-3.67%)
BABA   119.09 (-1.06%)
NIO   23.91 (-3.86%)
AMD   112.07 (-3.83%)
CGC   7.32 (-1.08%)
MU   81.45 (-1.81%)
GE   90.74 (-6.37%)
T   26.35 (+0.04%)
F   19.93 (-2.26%)
DIS   136.13 (-0.97%)
AMC   16.15 (-2.94%)
PFE   52.54 (+1.94%)
ACB   4.19 (-3.01%)
BA   203.10 (-0.54%)
S&P 500   4,387.25 (-0.52%)
DOW   34,410.84 (+0.13%)
QQQ   347.16 (-1.74%)
AAPL   160.17 (-0.90%)
MSFT   291.99 (-1.48%)
FB   303.68 (-1.63%)
GOOGL   2,568.25 (-1.83%)
AMZN   2,812.47 (-2.71%)
TSLA   924.20 (-0.62%)
NVDA   225.15 (-3.67%)
BABA   119.09 (-1.06%)
NIO   23.91 (-3.86%)
AMD   112.07 (-3.83%)
CGC   7.32 (-1.08%)
MU   81.45 (-1.81%)
GE   90.74 (-6.37%)
T   26.35 (+0.04%)
F   19.93 (-2.26%)
DIS   136.13 (-0.97%)
AMC   16.15 (-2.94%)
PFE   52.54 (+1.94%)
ACB   4.19 (-3.01%)
BA   203.10 (-0.54%)
S&P 500   4,387.25 (-0.52%)
DOW   34,410.84 (+0.13%)
QQQ   347.16 (-1.74%)
AAPL   160.17 (-0.90%)
MSFT   291.99 (-1.48%)
FB   303.68 (-1.63%)
GOOGL   2,568.25 (-1.83%)
AMZN   2,812.47 (-2.71%)
TSLA   924.20 (-0.62%)
NVDA   225.15 (-3.67%)
BABA   119.09 (-1.06%)
NIO   23.91 (-3.86%)
AMD   112.07 (-3.83%)
CGC   7.32 (-1.08%)
MU   81.45 (-1.81%)
GE   90.74 (-6.37%)
T   26.35 (+0.04%)
F   19.93 (-2.26%)
DIS   136.13 (-0.97%)
AMC   16.15 (-2.94%)
PFE   52.54 (+1.94%)
ACB   4.19 (-3.01%)
BA   203.10 (-0.54%)
S&P 500   4,387.25 (-0.52%)
DOW   34,410.84 (+0.13%)
QQQ   347.16 (-1.74%)
AAPL   160.17 (-0.90%)
MSFT   291.99 (-1.48%)
FB   303.68 (-1.63%)
GOOGL   2,568.25 (-1.83%)
AMZN   2,812.47 (-2.71%)
TSLA   924.20 (-0.62%)
NVDA   225.15 (-3.67%)
BABA   119.09 (-1.06%)
NIO   23.91 (-3.86%)
AMD   112.07 (-3.83%)
CGC   7.32 (-1.08%)
MU   81.45 (-1.81%)
GE   90.74 (-6.37%)
T   26.35 (+0.04%)
F   19.93 (-2.26%)
DIS   136.13 (-0.97%)
AMC   16.15 (-2.94%)
PFE   52.54 (+1.94%)
ACB   4.19 (-3.01%)
BA   203.10 (-0.54%)
NASDAQ:IPHA

Innate Pharma Stock Forecast, Price & News

$3.74
+0.03 (+0.81%)
(As of 01/25/2022 01:41 PM ET)
Add
Compare
Today's Range
$3.74
$3.86
50-Day Range
$3.71
$5.29
52-Week Range
$3.02
$11.95
Volume
5,020 shs
Average Volume
32,879 shs
Market Capitalization
$296.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.66
30 days | 90 days | 365 days | Advanced Chart
Receive IPHA News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.


Innate Pharma logo

About Innate Pharma

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

Headlines

Innate Pharma S.A.: Innate Pharma Third Quarter 2021 Report
November 16, 2021 |  finanznachrichten.de
Innate Pharma Third Quarter 2021 Report
November 16, 2021 |  finance.yahoo.com
Pre-market Movers: CRVS, ABCL, BGNE, IPHA, IRNT…
September 17, 2021 |  markets.businessinsider.com
Why Innate Pharma Shares Are Rising On Friday?
September 3, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IPHA
Fax
N/A
Employees
244
Year Founded
N/A

Sales & Book Value

Annual Sales
$80.47 million
Cash Flow
$0.44 per share
Book Value
$2.26 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$296.69 million
Optionable
Not Optionable

Company Calendar

Today
1/25/2022
Next Earnings (Estimated)
3/17/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

998th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

153rd out of 206 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Innate Pharma (NASDAQ:IPHA) Frequently Asked Questions

Is Innate Pharma a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Innate Pharma stock.
View analyst ratings for Innate Pharma
or view top-rated stocks.

How has Innate Pharma's stock price been impacted by Coronavirus?

Innate Pharma's stock was trading at $6.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IPHA stock has decreased by 40.6% and is now trading at $3.74.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Innate Pharma?

Innate Pharma saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 106,600 shares, an increase of 247.2% from the December 15th total of 30,700 shares. Based on an average daily volume of 84,000 shares, the days-to-cover ratio is presently 1.3 days.
View Innate Pharma's Short Interest
.

When is Innate Pharma's next earnings date?

Innate Pharma is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Innate Pharma
.

What price target have analysts set for IPHA?

4 Wall Street analysts have issued 1 year price objectives for Innate Pharma's shares. Their forecasts range from $9.00 to $14.00. On average, they anticipate Innate Pharma's stock price to reach $11.13 in the next twelve months. This suggests a possible upside of 197.5% from the stock's current price.
View analysts' price targets for Innate Pharma
or view top-rated stocks among Wall Street analysts.

Who are Innate Pharma's key executives?

Innate Pharma's management team includes the following people:
  • Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 63, Pay $789.78k)
  • Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (Age 48, Pay $364.41k)
  • Ms. Laure-Helene Mercier M.B.A., M.Sc., MSc, MBA, Exec. VP of Fin. & Corp. Strategy (Age 43, Pay $305.15k)
  • Dr. Herve Brailly, Co-Founder & Chairman of Supervisory Board (Age 60)
  • Dr. François Romagné, Founder (Age 57)
  • Mr. Eric Vivier D.V.M., M.B.A., Ph.D., Founder, Sr. VP & Chief Scientific Officer (Age 57)
  • Dr. Marc Bonneville, Founder (Age 61)
  • Mr. Jean Jacques Fournié Ph.D., Founder
  • Mr. Alessandro Moretta M.D., Ph.D., Founder
  • Mr. Frederic Lombard M.B.A., Sr. VP & CFO

What is Hervé Brailly's approval rating as Innate Pharma's CEO?

4 employees have rated Innate Pharma CEO Hervé Brailly on Glassdoor.com. Hervé Brailly has an approval rating of 100% among Innate Pharma's employees. This puts Hervé Brailly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Innate Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innate Pharma investors own include Cidara Therapeutics (cdtx), VBI Vaccines (VBIV), Ocular Therapeutix (OCUL), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), INmune Bio (INMB), Pluristem Therapeutics (PSTI) and (SNY).

When did Innate Pharma IPO?

(IPHA) raised $80 million in an initial public offering (IPO) on Thursday, October 17th 2019. The company issued 10,700,000 shares at $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO.

What is Innate Pharma's stock symbol?

Innate Pharma trades on the NASDAQ under the ticker symbol "IPHA."

How do I buy shares of Innate Pharma?

Shares of IPHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innate Pharma's stock price today?

One share of IPHA stock can currently be purchased for approximately $3.74.

How much money does Innate Pharma make?

Innate Pharma has a market capitalization of $296.69 million and generates $80.47 million in revenue each year.

How many employees does Innate Pharma have?

Innate Pharma employs 244 workers across the globe.

What is Innate Pharma's official website?

The official website for Innate Pharma is www.innate-pharma.com.

Where are Innate Pharma's headquarters?

Innate Pharma is headquartered at 117 AVENUE DE LUMINY BP 30191, MARSEILLE I0, 13009.

How can I contact Innate Pharma?

Innate Pharma's mailing address is 117 AVENUE DE LUMINY BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-4-30-30-30-30 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.